News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
YM BioSciences Completes Pivotal Phase III Trial Recruitment
October 21, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA). David Allan, Chairman and CEO, will be presenting at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
MORE ON THIS TOPIC
IN PARTNERSHIP WITH DIA
Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit
May 8, 2025
·
1 min read
·
Lori Ellis
Gene therapy
CRISPR’s Casgevy on the Rise With More Gene Therapy Proof of Concept To Come in 2025
May 7, 2025
·
4 min read
·
Annalee Armstrong
Huntington’s disease
PTC Nosedives Despite Claiming Phase II Win for Huntington’s Hopeful
May 5, 2025
·
2 min read
·
Dan Samorodnitsky
Policy
HHS To Require Placebo-Controlled Trials for All New Vaccines in ‘Radical Departure’ From Past
May 1, 2025
·
3 min read
·
Heather McKenzie
